Articles On ImpediMed (ASX:IPD)

Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so   As the end-of-October quarterly reporting...

Medical technology company ImpediMed (ASX:IPD) continues to make strides with its SOZO® Digital Health Platform, reporting significant progress in its Q1 FY25 results. The company’s pipeline for SOZO units increased by 34%, with 28 units so...

Control Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies the health sector stunners Noxopharm finds a drug manufacturer to kick-start its lupus trial   Health Check is renowned biotech journo Tim Bo...

The ASX is anticipated to experience a slight decline at the opening on Tuesday, following Wall Street's gains as investors analyze comments from U.S. policymakers. At 8 AM AEST, the SPI ASX200 futures contract indicated a decrease of 0.1%....

ASX set for slight drop as investors digest Fed comments Fed officials hint at potential future rate cuts Gold prices hit record highs while Tesla and Boeing rise   The ASX is looking at a slight drop when the market opens on Tuesday desp...

Stockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event highlighted some of ASX’s leading and up-and-coming biotech and life sciences companies Imricor Medical Systems, Race Oncology, Clarity Pha...

When I last covered ImpediMed (ASX:IPD) in May last year, I opined that the time-honoured way of lifting team performance was to replace the coach – a ploy that works about as often as it doesn’t. Back then, Rick Valencia had just replaced...

ASX health stocks dropped 1.74% in the past five days, while the broader markets rose 1.55% Power confident US Fed’s 50 basis points cut in cash rate this week will bring more optimism to the sector  Morgans, investor relations firm IR Dep...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Broker Rating Changes (Post Thursday Last Week) Upgrade DOMAIN HOLDINGS AUSTRALIA LI...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today’s Reports: ((AIS)) – Aeris...

ASX health stocks dropped 1.22% in the past four days, while the broader markets fell 1.35% Morgans downgrades Ramsay Health Care following its FY24 results, believes a ‘near-term earnings recovery looks challenging’ Percheron reports posi...

ASX health stocks flat for week in line while broader markets rise of 0.5% Nanosonics has risen ~17% in the past five days on its FY24 result Mach7 falls falls as investing in growth plans push out profit expectations    Healthcare and li...

Stockhead joins with IR Department and Morgans for HealthInvest 2024 in Sydney in September Event to highlight some of ASX’s leading up-and-coming health and life sciences companies Clarity Pharmaceuticals, Percheron Therapeutics, Imricor,...

ASX health stocks rise 0.9% in past five days as broader markets lift 1.2%, despite Friday selloff ImpediMed’s latest quarterly result shows sales momentum building for Sozo device  Cold-cathode X-ray machine developer MicroX makes progres...

The ASX200 had a strong start to the week rising 0.86% to 7989.60 points – not far off the recently hit 8000 level. Investors are anticipating the release of key Australian inflation data on Wednesday. The US Federal Reserve also makes a...

ASX health stocks fall 0.19% in past five days as broader markets lift 0.79% Morgans says capital raises remain a theme for 2024 among healthcare stocks Pharmaceutical distributor EBOS increases stake in MedAdvisor to 9.8% Healthcare and...

Echo IQ is awaiting FDA approval for its AI-powered EchoSolv platform EchoSolv utilises machine learning algorithms to detect aortic stenosis Stockhead reached out to Echo IQ’s COO, Deon Strydom   When looking at a healthcare stock to buy...

In 2024 several ASX medtech companies have upcoming catalysts as they strive to innovate healthcare  Primary results of EBR’s SOLVE trial expected to be published in a leading peer reviewed journal in coming months ImpediMed is focusing in...

ASX health stock fall in past five days in line with broader markets as economic and geopolitical factors weigh heavily ResMed falls as Eli Lily reports positive Phase 3 results of weight-loss drug in obese people with obstructive sleep ap...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.091% to 7,605.60. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spot...

Provaris Energy has seen its directors strongly support its recent placement  Greentech Metals executive director sees bear lithium market as chance to buy up New board directors of ImpediMed show their confidence in growth prospects of bi...

New ImpediMed leadership team and board committed to company’s success  Private payor and Medicare coverage for SOZO device reaches critical mass in 16 US states ImpediMed prioritises 11 US states for growth as looks to boost sales and ach...

ASX health sector lifts in line with broader markets as reporting season comes to end Morgans upgrades Polynovo as total revenue rises 65.6% on pcp to $48.8 million  Nanosonics cites hospital budgetary pressures as deferring purchasing dec...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABG)) - Abacus Group ((ABC)) - Adbri ((AHL)) - Adrad ((AMX)) - Aerometrex ((ALU)) - Altium ((AWC)) - Alumina Ltd ((ATG)) - Articore Group ((ANG)) - Austin Engineering ((...

ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel...

ASX health sector up in line with broader market but some names ail after quarterly results Cochlear lifts net profit guidance for FY24 after stronger than expected first half sales revenue  CSL to report half year results next week with b...

ASX health stocks flat in past five days in line with broader markets  Avita lowers full year 2023 guidance after slower progress in its customer’s VAC processes EBOS decides against acquisition of animal care business, reportedly Greencro...

After early gains, ASX200 finished off the day pretty even – up only .13 of a per cent.  Energy stocks led the gainers, up 1.4 per cent, fuelled by news the Organisation of Petroleum Exporting Countries (OPEC) is looking to cut output to...

Two ASX All Ords shares announced significant changes among their top brass today. And investors reacted by hitting the sell button. While the All Ordinaries Index (ASX: XAO) is up 0.2% at the time of writing, both All Ords shares are in t...

ASX to open higher on Monday after Wall Street’s third straight weekly gains ChargePoint tumbled -35pc, while GAP surged over 30pc And which are the most innovative companies in the world?   Aussie shares are poised to open higher on Mond...

ImpediMed makes leadership and board changes to enhance growth and manage costs effectively Rick Valencia will step down from his role as Managing Director and CEO effective immediately Dr. Parmjot Bains takes on the role of Interim C...

At the $240 million Perennial Better Future Trust, healthcare stocks are a critical component of our ESG-focused portfolio. These stocks, many of which have global reach, have the potential to generate attractive returns while shaping a bet...

ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp...

The Australian stock market has surged around midday, buoyed by the positive performance on Wall Street, amid growing optimism that the Federal Reserve might have concluded its series of interest rate hikes. At noon, the S&P/ASX 200 is...

  To register for today's webinar click here. Findi (ASX:FND) has extended the existing State Bank of India contract until 30 September 2024. Commenting on the SBI contract extension, Findi Chairman Mr Nicholas Smedley said: “The SBI contra...

03 Nov 2023 - A snapshot of the stocks on the move, featuring Findi (ASX:FND), Immutep (ASX:IMM) and ImpediMed (ASX:IPD).

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

Bod Science confirm the effectiveness of Aqua Phase technology ImpediMed announces new chief medical officer   Bod Science set to commercialise Aqua Phase Cannabis focused biotech, Bod Science (ASX:BOD), surged 12% this morning after prov...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

Polynovo Ltd (ASX: PNV) shares have struggled to find support in 2023. After a brief reprieve between May and August, the wound treatment company has seen its share price slapped with a 22.3% decline over the last 29 days. On Friday, shar...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AGI)) - Ainsworth Game Technology ((ALX)) - Atlas Arteria ((ATA)) - Atturra ((AUA)) - Audeara ((ASB)) - Austal ((BUB)) - Bubs Australia ((CCX))...

ASX healthcare stocks haven’t done so well as a collective over the past 12 months. The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 8% over the past year. By comparison, the market benchmark S&P/ASX 200 Index (ASX: XJO) is u...

US healthcare company, CurveBeam AI, is preparing to debut on the ASX today after concluding its pre-initial public offering (IPO) private placement of $25 million. CurveBeam will be listed under the ticker code ‘CVB,’ providing investor...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

World Overnight SPI Overnight 7360.00 – 39.00 – 0.53% S&P ASX 200 7450.70 + 40.30 0.54% S&P500 4576.73 – 12.23 – 0.27% Nasdaq Comp 14283.91 – 62.11 – 0.43% DJIA 35630.68 + 71.15 0.20% S&P500 VIX 13.93 + 0.30 2.20%...

World Overnight SPI Overnight 7383.00 + 25.00 0.34% S&P ASX 200 7410.40 + 6.80 0.09% S&P500 4588.96 + 6.73 0.15% Nasdaq Comp 14346.02 + 29.37 0.21% DJIA 35559.53 + 100.24 0.28% S&P500 VIX 13.63 + 0.30 2.25% US 10...

Weekly update on stockbroker recommendation, target price, and earnings forecast changes. By Mark Woodruff Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquari...

The S&P/ASX 200 Index (ASX: XJO) is on form again and on track to record a small gain. In afternoon trade, the benchmark index is up 0.2% to 7,340 points. Four ASX shares that have failed to follow the market higher today are listed...

The Energy sector demonstrated strong growth, with a rally of 1.7%. Ampol (ASX:ALD) experienced a significant surge of 4.4% following robust fuel sale volumes reported for the first half of the financial year 2023. Woodside Petroleum (ASX:W...

Woodside Energy (ASX:WPL), reported a 29% decline in revenue for the second quarter, amounting to $US3.1 billion (A$4.5 billion). Sales of oil decreased by 4%, with 48.4 million barrels sold, while production experienced a 5% drop to 44.5 m...